CVRx Q4 Revenue $16.02M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy CVRX?
Reports Q4 revenue $16.02M, consensus $15.83M. "We achieved key foundational goals in 2025, and we're heading into 2026 with increasing momentum. Our sales team is building experience and becoming more effective, and we're seeing strong support at high-potential centers. Additionally, the new Category I CPT codes, effective January 1st, remove automatic prior authorization denials. Finally, the initiation of the landmark BENEFIT-HF trial under CMS Category B IDE coverage is a major step that could allow us to triple our addressable market," said Kevin Hykes, President and Chief Executive Officer of CVRx. "We're confident that these developments will support our accelerated growth and make Barostim therapy more accessible for heart failure patients in the coming year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.850
Low
11.00
Averages
12.50
High
14.00
Current: 4.850
Low
11.00
Averages
12.50
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite bringing in several high-quality sales representatives, many are still in the early stages of territory development, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the poor performance announcement on April 8, CVRx's stock fell by $5.34, a 46.3% drop, and on May 9, the stock fell another $3.01, or 38.8%, severely impacting investor interests.
- Integration Challenges: During the February 12, 2026 earnings call, CVRx noted that integrating new sales representatives has created near-term growth impacts, leading to a stock price decline of $0.74, or 13.0%, highlighting the challenges the company faces in its sales organization.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Revenue Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite hiring new high-quality sales representatives, many are still in early territory development stages, which negatively impacted investor confidence.
- Stock Price Plunge: Following the disappointing earnings announcement on April 8, 2025, CVRx's stock fell by $5.34, or 46.3%, closing at $6.20, which directly affected investor assets and trust in the company.
- Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management citing more significant than anticipated changes in the salesforce, further eroding market confidence.
- Ongoing Losses: On February 12, 2026, CVRx reported its Q4 and full-year results for 2025, with stock prices dropping by $0.74, or 13.0%, to close at $4.95 due to management's deep adjustments within the sales organization, exacerbating investor losses.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite hiring several high-quality sales representatives, many are still in the early stages of territory development, which has negatively impacted investor confidence.
- Stock Price Crash: Following the Q1 results announcement, CVRx's stock plummeted by $5.34, or 46.3%, closing at $6.20 on April 8, 2025, directly affecting the value of investors' holdings.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, further undermining market confidence.
- Ongoing Losses: In the Q4 and full-year 2025 report on February 12, 2026, CVRx's stock fell by $0.74, or 13.0%, closing at $4.95, highlighting the challenges the company faces in integrating new sales representatives effectively.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, which could negatively impact investor confidence.
- Performance Decline: On April 7, 2025, CVRx announced preliminary first-quarter results that fell short of expectations, causing its stock price to plummet by 46.3% to close at $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes revealed significant changes in the sales team, with 25% of territory managers replaced in just a few months, further exacerbating market concerns about the company's future performance.
- Continued Stock Price Drop: Following the poor performance and lowered full-year revenue guidance, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor pessimism regarding the company's outlook.
See More
CVRx Q4 2025 Earnings Call Insights
- Revenue Growth: CVRx reported fourth-quarter revenue of $16 million and full-year revenue of $56.7 million, reflecting growth of 4% and 10% respectively, indicating the company's stable growth potential in the market.
- Market Opportunity: With 339,000 patients eligible for Barostim therapy, representing a $10.5 billion market opportunity with less than 1% penetration, the company is strategically focused on increasing its market share.
- Strategic Priorities: The company aims to build a world-class sales organization, drive deep adoption in targeted centers, and reduce barriers to adoption, having expanded to 53 territories with 252 active implanting centers, marking increases of 10% and 13% respectively.
- Financial Outlook: For 2026, total revenue is expected to range between $63 million and $67 million, with gross margins between 84% and 86%, as management expresses optimism about future growth, particularly with the new CPT code implementation reducing reimbursement friction.
See More
CVRx Reports Q4 Earnings Beat with Revenue Growth
- Earnings Report: CVRx's Q4 GAAP EPS of -$0.46 missed expectations by $0.02, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported $16 million in revenue, a 4.6% year-over-year increase that beat market expectations by $0.17 million, reflecting improved sales performance in the medical device sector.
- Future Outlook: At the 44th Annual J.P. Morgan Healthcare Conference, CVRx presented preliminary 2025 results and issued guidance for 2026, demonstrating confidence in future growth prospects.
- Market Reaction: Although the EPS fell short of expectations, the revenue growth and future guidance may positively influence investor sentiment, increasing market interest in CVRx.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite bringing in several high-quality sales representatives, many are still in the early stages of territory development, which has undermined investor confidence.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, raising further concerns about the company's future.
- Stock Price Plunge: Following the poor performance announcement on April 8, CVRx's stock fell by $5.34, a 46.3% drop, and on May 9, the stock fell another $3.01, or 38.8%, severely impacting investor interests.
- Integration Challenges: During the February 12, 2026 earnings call, CVRx noted that integrating new sales representatives has created near-term growth impacts, leading to a stock price decline of $0.74, or 13.0%, highlighting the challenges the company faces in its sales organization.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Revenue Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite hiring new high-quality sales representatives, many are still in early territory development stages, which negatively impacted investor confidence.
- Stock Price Plunge: Following the disappointing earnings announcement on April 8, 2025, CVRx's stock fell by $5.34, or 46.3%, closing at $6.20, which directly affected investor assets and trust in the company.
- Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management citing more significant than anticipated changes in the salesforce, further eroding market confidence.
- Ongoing Losses: On February 12, 2026, CVRx reported its Q4 and full-year results for 2025, with stock prices dropping by $0.74, or 13.0%, to close at $4.95 due to management's deep adjustments within the sales organization, exacerbating investor losses.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: CVRx reported only $12.3 million in revenue for Q1 2025, indicating that despite hiring several high-quality sales representatives, many are still in the early stages of territory development, which has negatively impacted investor confidence.
- Stock Price Crash: Following the Q1 results announcement, CVRx's stock plummeted by $5.34, or 46.3%, closing at $6.20 on April 8, 2025, directly affecting the value of investors' holdings.
- Revenue Guidance Cut: On May 8, 2025, CVRx slashed its full-year revenue guidance to between $55 million and $58 million, with management stating that changes in the salesforce were more significant than initially anticipated, further undermining market confidence.
- Ongoing Losses: In the Q4 and full-year 2025 report on February 12, 2026, CVRx's stock fell by $0.74, or 13.0%, closing at $4.95, highlighting the challenges the company faces in integrating new sales representatives effectively.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, which could negatively impact investor confidence.
- Performance Decline: On April 7, 2025, CVRx announced preliminary first-quarter results that fell short of expectations, causing its stock price to plummet by 46.3% to close at $6.20 per share the following day, indicating market disappointment with the company's performance.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes revealed significant changes in the sales team, with 25% of territory managers replaced in just a few months, further exacerbating market concerns about the company's future performance.
- Continued Stock Price Drop: Following the poor performance and lowered full-year revenue guidance, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, reflecting investor pessimism regarding the company's outlook.
See More
CVRx Q4 2025 Earnings Call Insights
- Revenue Growth: CVRx reported fourth-quarter revenue of $16 million and full-year revenue of $56.7 million, reflecting growth of 4% and 10% respectively, indicating the company's stable growth potential in the market.
- Market Opportunity: With 339,000 patients eligible for Barostim therapy, representing a $10.5 billion market opportunity with less than 1% penetration, the company is strategically focused on increasing its market share.
- Strategic Priorities: The company aims to build a world-class sales organization, drive deep adoption in targeted centers, and reduce barriers to adoption, having expanded to 53 territories with 252 active implanting centers, marking increases of 10% and 13% respectively.
- Financial Outlook: For 2026, total revenue is expected to range between $63 million and $67 million, with gross margins between 84% and 86%, as management expresses optimism about future growth, particularly with the new CPT code implementation reducing reimbursement friction.
See More
CVRx Reports Q4 Earnings Beat with Revenue Growth
- Earnings Report: CVRx's Q4 GAAP EPS of -$0.46 missed expectations by $0.02, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported $16 million in revenue, a 4.6% year-over-year increase that beat market expectations by $0.17 million, reflecting improved sales performance in the medical device sector.
- Future Outlook: At the 44th Annual J.P. Morgan Healthcare Conference, CVRx presented preliminary 2025 results and issued guidance for 2026, demonstrating confidence in future growth prospects.
- Market Reaction: Although the EPS fell short of expectations, the revenue growth and future guidance may positively influence investor sentiment, increasing market interest in CVRx.
See More
